Itoco Inc. (ITMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 228.37 Thousand USD | -15.65% |
| 2021 | 270.76 Thousand USD | -8.52% |
| 2020 | 295.98 Thousand USD | 50.86% |
| 2019 | 196.19 Thousand USD | 4.57% |
| 2018 | 187.62 Thousand USD | -5.27% |
| 2017 | 198.05 Thousand USD | 115.69% |
| 2016 | 91.82 Thousand USD | -53.61% |
| 2015 | 197.92 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2009 | 2.15 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 228.39 Thousand USD | 0.01% |
| 2023 Q2 | 228.39 Thousand USD | 0.0% |
| 2023 Q3 | 228.4 Thousand USD | 0.01% |
| 2022 Q1 | 452.18 Thousand USD | 67.0% |
| 2022 Q3 | 538.8 Thousand USD | 94.96% |
| 2022 FY | 228.37 Thousand USD | -15.65% |
| 2022 Q4 | 228.37 Thousand USD | -57.61% |
| 2022 Q2 | 276.36 Thousand USD | -38.88% |
| 2021 Q1 | 505.9 Thousand USD | 0.0% |
| 2021 FY | 270.76 Thousand USD | -8.52% |
| 2021 Q4 | 270.76 Thousand USD | -40.08% |
| 2021 Q3 | 451.88 Thousand USD | 3.67% |
| 2021 Q2 | 435.9 Thousand USD | -13.84% |
| 2020 FY | 295.98 Thousand USD | 50.86% |
| 2019 FY | 196.19 Thousand USD | 4.57% |
| 2018 FY | 187.62 Thousand USD | -5.27% |
| 2017 FY | 198.05 Thousand USD | 115.69% |
| 2016 FY | 91.82 Thousand USD | -53.61% |
| 2015 FY | 197.92 Thousand USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2010 Q2 | 3.77 Million USD | -15.41% |
| 2010 Q3 | 3.12 Million USD | -17.1% |
| 2010 Q1 | 4.45 Million USD | 107.3% |
| 2009 FY | 2.15 Million USD | 0.0% |
| 2009 Q4 | 2.15 Million USD | -50.25% |
| 2009 Q3 | 4.32 Million USD | 1252875.07% |
| 2009 Q2 | 345.00 USD | 1.17% |
| 2009 Q1 | 341.00 USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.446% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 94.46% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.169% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.473% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.233% |
| Mesoblast Limited | 118.7 Million USD | 99.808% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 75.916% |
| Genus plc | 233.1 Million USD | 99.902% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 92.207% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 83.002% |
| Marizyme, Inc. | 18.71 Million USD | 98.78% |
| ContraFect Corporation | 2.88 Million USD | 92.073% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 69.55% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -68.56% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 84.21% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 90.181% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.964% |
| MultiCell Technologies, Inc. | 202.58 USD | -112634.228% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.603% |
| EV Biologics, Inc. | 1.49 Million USD | 84.721% |
| Q BioMed Inc. | 4.1 Million USD | 94.443% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.31% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 63.754% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 81.408% |
| Biomind Labs Inc. | 735.54 Thousand USD | 68.951% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.867% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.243% |
| Skye Bioscience, Inc. | 4.61 Million USD | 95.052% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 74.284% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -61.377% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 96.11% |
| IMV Inc. | 28.88 Million USD | 99.209% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -787.97% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 89.888% |
| GB Sciences, Inc. | 1.75 Million USD | 87.019% |
| Alpha Cognition Inc. | 1.22 Million USD | 81.286% |
| HST Global, Inc. | 98.31 Thousand USD | -132.282% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -52.251% |
| Enzolytics Inc. | 996.33 Thousand USD | 77.078% |
| Resverlogix Corp. | 6.49 Million USD | 96.482% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 52.172% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 10.648% |
| argenx SE | 20 Million USD | 98.858% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.499% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 91.569% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2133.516% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.945% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -13.838% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 90.475% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 0.399% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.662% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 92.453% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 36.511% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.877% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -53.63% |
| BioStem Technologies, Inc. | 4.71 Million USD | 95.153% |
| ONE Bio Corp. | 19.71 Million USD | 98.842% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 8.716% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 8.179% |
| Agentix Corp. | 50 Thousand USD | -356.754% |
| LadRx Corporation | 33.6 Thousand USD | -579.572% |
| Cell Source, Inc. | 9.25 Million USD | 97.532% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 69.8% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 69.8% |
| NovAccess Global Inc. | 2.19 Million USD | 89.619% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.771% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8.248% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.417% |
| Kadimastem Ltd | 891.22 Thousand USD | 74.375% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 43.168% |
| CytoDyn Inc. | 30.07 Million USD | 99.241% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 52.842% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 35.092% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.08% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -86.43% |
| Rebus Holdings, Inc. | 310 Thousand USD | 26.33% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 95.177% |
| International Stem Cell Corporation | 4.17 Million USD | 94.534% |
| Bioxytran, Inc. | 1.92 Million USD | 88.136% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -265.913% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 89.528% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.254% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.34% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 85.318% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 14.785% |
| Neutra Corp. | 54.15 Thousand USD | -321.702% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 87.52% |
| PureTech Health plc | 25.51 Million USD | 99.105% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 81.345% |
| IXICO plc | 472.02 Thousand USD | 51.617% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.527% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.633% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.754% |